GSK in HIV drug deal with Shionogi
GlaxoSmithKline has beefed up its interest in an HIV drug which analysts regard as a potential multi-billion-dollar-a-year blockbuster.
A new deal with Shionogi sees Britain's biggest pharmaceuticals company give the Japanese drug maker a 10 per cent stake in Viiv Healthcare – an HIV drug joint venture set up in 2009 between GSK and Pfizer – in exchange for its rights to dolutegravir, a once-daily HIV medicine hich has performed well in clinical trials.
Previously, income from the medicine would have been shared 50/50 between Viiv and Shionogi, where now GSK will earn as much as 66 per cent from the drug.
- 1 Stephen Fry explains what he would say if he was 'confronted by God'
- 2 Venezuela Expo Tattoo 2015: Extreme body art from 'Vampire Woman' to 109mm earlobes
- 4 Ball pool for adults opens in London
Stephen Fry explains what he would say if he was 'confronted by God'
9 reasons Greece's experiment with the radical left is doomed to failure
Have we reached 'peak food'? Shortages loom as global production rates slow
British grandmother Lindsay Sandiford faces execution by firing squad in Indonesia
Liberal Democrat minister defends comments suggesting immigration causes pub closures
Hard line on immigration could cost Tories the election
iJobs Money & Business
£40000 - £50000 per annum: Recruitment Genius: This is an exciting opportunity...
£30000 - £35000 per annum + Benefits: Ashdown Group: Marketing Manager - Marke...
£13000 per annum: Recruitment Genius: This Pension Specialist was established ...
£23000 - £26000 per annum + Benefits: Ashdown Group: Market Research Executive...